[Federal Register Volume 75, Number 180 (Friday, September 17, 2010)] [Rules and Regulations] [Page 56858] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2010-23195] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 2 [Docket No. FDA-2006-N-0304] (formerly Docket No. 2006N-0262) RIN 0910-AF93 Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Flunisolide, etc.); Correction AGENCY: Food and Drug Administration, HHS. ACTION: Final rule; correction. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone- depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The document was published with an inadvertent error. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Diane Sullivan, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171. SUPPLEMENTARY INFORMATION: In FR Doc. 2010-8467, appearing on page 19213, in the Federal Register of Wednesday, April 14, 2010, the following correction is made: 1. On page 19213, in the third column, the heading ``RIN 0910- AF92'' is corrected to read ``RIN 0910-AF93''. Dated: September 13, 2010. David Dorsey, Acting Deputy Commissioner for Policy, Planning and Budget. [FR Doc. 2010-23195 Filed 9-16-10; 8:45 am] BILLING CODE 4160-01-S